anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses tea soup for treating infantile malnutrition and a preparation method thereof. The tea soup is prepared from 100-110 parts by weight of brick tea, 30-32 parts by weight of tea stalks, 3-4 parts by weight of chicken's gizzard membrane, 2-3 parts by weight of bighead atractylodes rhizome, 4-5 parts by weight of Chinese yam, 4-5 parts by weight of haw, 0.1-0.2 parts by weight of polyphenoloxidase, 5-6 parts by weight of anthocyanidin and 30-32 parts by weight of diatomite. The black tea satisfying black tea quality index requirements is added with low-fluorine raw materials such as tea stalks in blending so that product fluorine content is reduced. Through use of diatomite, fluorinions are adsorbed so that fluorine content is further reduced. Through use of anthocyanidin, the product is rich in nutrients, has brilliant and beautiful colors. Polyphenoloxidase can oxidize tea polyphenol in the tea soup so that tea soup color change is avoided in storage. The tea soup contains a plurality of Chinese herbal medicine components and can treat infantile malnutrition.
Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks. To be compared with the placebo (exercise under normoxia) group.
<P>PROBLEM TO BE SOLVED: To provide a Salmonella infection inhibitor for a poult, capable of exhibiting excellent effects by being administered to the poult as early as possible from the hatching, and to provide a method for inhibiting the Salmonella infection of the poult by using the inhibitor.  <P>SOLUTION: The Salmonella infection inhibitor for the poult comprises gluconic acids as active ingredient. The Salmonella infection-inhibiting diet rich composition for the poult is obtained by adding the Salmonella infection inhibitor for the poult. The method for inhibiting the Salmonella infection of the poult includes a step for administering the Salmonella infection inhibitor for the poult or the Salmonella infection-inhibiting diet rich composition for the poult in an effective amount to the poult. The use of the gluconic acids for the production of the composition for inhibiting the Salmonella infection of the poult is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Triphala is renowned for its curative attributes and has been utilized for centuries to address diverse health ailments. Moreover, the active component of Triphala, polyphenols, is widely recognized for its excellent pharmacological activities, such as anti-inflammatory properties, and has been utilized as a potential natural remedy. However, the precise mechanism through which Triphala alleviates cognitive dysfunction and anxiety induced by chronic sleep deprivation (SD) remains restricted. The objective of this investigation is to examine and clarify the potential mechanism of action that underlies the therapeutic benefits of Triphala in addressing cognitive dysfunction and anxiety induced by chronic SD. Our results demonstrated that Triphala significantly alleviates chronic SD-induced behavioral abnormalities. Additionally, Triphala was highly effective at preventing histopathological or morphological damage to neurons located in the hippocampus. The therapeutic effects of Triphala in treating cognitive dysfunction and anxiety induced by chronic SD involve the modulation of several biological pathways, including inflammation and immune responses, oxidative stress, cell growth and differentiation, metabolism, and neurotransmitter communication. Moreover, our study illustrated that Triphala increased the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and significantly activated the Nrf2/hemeoxygenase-1 (HO-1) axis. Additionally, the neuroprotective properties of Triphala were found to be counteracted by the Nrf2 inhibitor ML385. Our study represented the first to unveil that Triphala exerts therapeutic benefits in alleviating chronic SD-induced cognitive deficits and anxiety by activation of the Nrf2/HO-1 axis. Triphala emerges as a promising nutraceutical ingredient for mitigating cognitive deficits and anxiety linked to chronic SD.
Participants will have CGM sensor placed at first visit and will be worn for 12 weeks. Sensor must be scanned 3 times daily. Adjustments to medication regimen will be recommended at 6 weeks. Follow-up appointments will be at 12 weeks and 24 weeks.
The teeth allocated in the experimental group will have the restorations carried out through monochromatic composite resin with chameleon effect in single insertion through polyvinyl crown. For this, 37% phosphoric acid (Condac37, FGM) will be applied for 15 seconds, and then, after washing and relative drying of the surface, application of universal adhesive (Universal Beautibond Adhesive, Shofu) with the aid of microbrush on the entire tooth surface, photoactivation of the adhesive and adaptation of the crown matrix in acetate filled with resin in the tooth. Photoactivation will be done for 20 seconds per dental face, and the acetate matrix is then removed. The tooth will receive finishing and polishing through rotating instruments and abrasive discs (Supersnap, Shofu).
PROCARE-I+ intervention will be designed as a brief 8-session with 4 additonal sessions (add-on modules) child-focused programme by adapting the core modules from UP-A. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
PURPOSE:To obtain the fitted capsule without deterioration and discoloring of a filler therein by using a heat gelling high molecular substance as a main component and gelling and drying the same by heating. CONSTITUTION:In an aqueous solution based on a heat gelling high molecular substance such as a hydroxypropyl cellulose, a capsule pin is immersed and said pin  is heated to an appropriate temp. to coat a pin surface with the high molecular substance. The pin is withdrawn upwardly and heated to gel the coating thereon and,  subsequently, dried. The dried gel is withdrawn from the pin and unnecessary parts are cut to make the fit capsule. By the above described method, the sheath capsule  more excellent than a gelatine capasule can be prepared without generating deficiencies such as crack or the like.
NEW MATERIAL:The compound of formula I (n is 8-16). EXAMPLE:N-lauroyl-N-(2-hydroxypropyl)-beta-alanine. USE:A surfactant. Useful for cleaning agent for the hair and skin of infants and kitchen detergent, etc., because of its low irritation and high resistance to hard water. PREPARATION:The compound of formula I can be produced by reacting a fatty acid chloride of formula II with N-(2-hydroxypropyl)-beta-alanine sodium salt according to the reaction formula. Concretely, the reaction is performed by dripping the compound of formula II at room temperature to an aqueous solution of the compound of formula III while controlling the pH of the solution to 10-12 with an aqueous solution of NaOH.
Thoracic paravertebral block (TPVB) application has also been used in recent years due to the lower incidence of side effects. The erector spinae plane block (ESPB)has been used as a part of multimodal analgesia in recent years. In ESPB is aimed to treat the postoperative pain of the thoracoabdominal region by injecting a local anesthetic into the interfacial area under the erector spinae muscle . ESPB creates an effect that covers the posterior and lateral thorax by affecting the dorsal rami and branches of the spinal nerves . Midtransverse process to pleura (MTP) block is less invasive as the position of the needle in this block is midway between the transverse process' posterior border and the pleura. Due to fenestrations present in the superior costotransverse ligament (SCTL), the drug reaches the paravertebral space
FIELD: agriculture. ^ SUBSTANCE: invention relates to agriculture, in particular to treatment of hooves of dairy animals. Bath for washing hooves of dairy animals includes the front end, the lateral side connected to the front end, the posterior end attached to the lateral side. The front end is located to the lateral side at an angle of less than 90. The system for washing hooves of dairy animals includes delivery system of chemicals composition into the bath for hooves treatment. The chemicals composition includes antimicrobial heavy metal salts, combinations thereof and additional antimicrobial components. ^ EFFECT: use of the invention enables to implement a qualitative treatment of hooves of dairy animals. ^ 19 cl, 18 dwg
Hereditary haemorrhagic telangiectasia is an inherited disorder characterised by vascular dysplasia that leads to the development of arteriovenous malformations. Pulmonary arteriovenous malformations occur in approximately 30% of patients with haemorrhagic telangiectasia. Given the complex characteristics of haemorrhagic telangiectasia lesions, the application of three-dimensional fusion imaging holds significant promise for procedural guidance and decrease in contrast and radiation dosing. We reviewed all patients who underwent transcatheter approach for pulmonary arteriovenous malformation occlusion with fusion image guidance from June 2018 to September 2023 from a single centre. A total of nine cases with haemorrhagic telangiectasia and transcatheter occlusion of pulmonary arteriovenous malformations using fusion imaging were identified. Five (56%) were male, mean age at procedure was 15.7 years (10-28 years) and mean number of pulmonary arteriovenous malformations intervened was three per patient (1-7). Two of the cases were complex repeat embolisations. The mean fluoroscopy time was 40.6 min (10.7-68.8 min), with mean contrast dose of 28.8 mL (11-60 mL; mean of 0.51 mL/kg) and mean radiation dose of 66.3 mGy (25.6-140 mGy; mean of 40.5 mGy/m2). There were no complications reported during the procedures, with no additional interventions necessary. Fusion imaging in pulmonary arteriovenous malformations embolisation for patients with haemorrhagic telangiectasia is feasible and has the potential to reduce contrast and radiation doses. To our knowledge, we describe the lowest radiation and contrast doses per patient using fusion imaging technology reported in the literature to date.
Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
The iUni G2 Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The study subjects will be followed for 10 years post implant. The study objective is to evaluate the safety and performance of the ConforMIS iUni® Unicompartmental Knee Resurfacing Device in patients with single compartment osteoarthritis. The iUni is a patient-specific unicompartmental resurfacing device designed from the patient's unique anatomy using proprietary software which interprets data from the patient's CT scan. The patient matched implant design is then coupled with unique patient-matched disposable instrumentation designed using the same CT data and software. The follow-up visit schedule will include visits at 6 weeks, 6 months (optional), 1 year, 2 years, 5 years and 10 years post implant.The remaining follow-up data collected at years 3, 4, 6, 7, 8, and 9 may be collected via phone call/email and does not require a subject visit to the site.The study sites will be located in the United States.
Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
(see WARNINGS and PRECAUTIONS): Patients should be advised about the potential for increased brown pigmentation of the iris, which may be permanent. Patients should also be informed about the possibility of eyelid skin darkening, which may be reversible after discontinuation of Latanoprost Ophthalmic Solution.

Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with Latanoprost Ophthalmic Solution. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients also should be advised that if they develop an intercurrent ocular condition (e.g., trauma, or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of the multiple-dose container.

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and lid reactions, they should immediately seek their physician’s advice.

Patients should also be advised that Latanoprost Ophthalmic Solution contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of Latanoprost Ophthalmic Solution.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
There is described an artificial intelligence wearable ECG skin patch (400) to detect sudden cardiac arrest. The wearable ECG monitoring patch (400) with AI based predictive analytics and remote based cardiac monitoring (615) system that can detect cardiac arrhythmias automatically in real-time and make a diagnosis with AI models trained with acquired data. The wearable skin has a biocompatible polymer patch (400) which captures the electrical signal through a flexible printed electronic technology based conducting ink and a substrate. The microcontroller controls (201), store and transmit the data packets. The IoT connected signal transmission is capable of recording and transferring the data packets through wireless communication. The AI engine is capable of analysing, evaluating, testing and providing the data packets of sudden cardiac arrest through a peak detector algorithm. The ECG skin patch (400) to detect and measure the sudden cardiac arrest with the R-R interval time series to obtain heart rate variability.
The deleterious effects of human activities on biodiversity in the vegetal and animal world, and on climate changes are now well-established facts. However, little is yet known on the impact of human activities on microbial diversity on the planet and more specifically on the human microbiota Large implementation of metagenomics allows exaustive microbial cataloguing with broad spatio-temporal resolution of human microbiota. A reduction in bacterial richness and diversity in the human microbiota, particularly in the intestinal tract, is now established and particularly obvious in the most industrialized regions of the planet. Massive, uncontrolled use of antibiotics, drastic changes in traditional food habits and some elements of the "global exposome" that remain to identify are usually considered as stressors accounting for this situation of "missing microbes". As a consequence, a dysbiotic situation develops, a "dysbiosis" being characterized by the erosion of the central core of shared bacterial species across individuals and the development of opportunistic "pathobionts" in response to a weaker barrier capacity of these impoverished microbiota. The current challenge is to establish a causality link between the extension of these dysbiotic situations and the steady emergence of epidemic, non-communicable diseases such as asthma, allergy, obesity, diabetes, autoimmune diseases and some cancers. Experimental animal models combined with controlled, prospective clinical interventions are in demand to consolidate causality links, with the understanding that in the deciphering of the mechanisms of alteration of the human-microbiome symbiosis resides a novel exciting chapter of medicine: "microbial medicine".
Aim: Aim of this study is to investigate the effects of interactive telerehabilitation exercises in office workers with chronic nonspecific neck pain. Methods: Office workers (n = 120) were randomly divided into three groups between February and July 2022, taking into account the inclusion and exclusion criteria, and office ergonomics training was given to all of the participants. Group 1 participants were given an interactive telerehabilitation program (strengthening, motor control, and posture correction exercises) for 45 min per day, 3 days a week, for a total of 6 weeks. Group 2 participants were trained to do the home exercise program on their own for 45 min per day, 3 days a week, for a total of 6 weeks. Only office ergonomics training was given to Group 3 patients. Results: Statistically significant improvement in pain (p < 0.001), range of motion (ROM) (p < 0.001), neck disability status (p < 0.001), functional status (p < 0.001), and quality of life (p < 0.001) of 6-week interactive telerehabilitation application in office workers was found. Discussion: In addition to office ergonomics training, interactive telerehabilitation program is the most effective method on pain, ROM, and neck disability compared with home exercise program and office ergonomics training alone, and studies are needed on the long-term effectiveness of telerehabilitation applications and telerehabilitation treatment diversity.
PURPOSE: To obtain an edible compsn. consisting of an entraining aq. phase contg. vitamin C and liposome having vitamin E in its lipid structure, preventing oxidation and excellent in shelf life during a long period of time. CONSTITUTION: This edible compsn. consists of an entraining aq. phase contg. vitamin C preferably having 10-80mg/cm<3> concn. and liposome having vitamin E in its lipid structure. The lipid compsn. of the liposome is formed from lecithin and consists of hardened lipid and unhardened lipid in a weight ratio of 1:1 to 4:9. The vitamin E exists in the lipid structure preferably in 1.5-7.1wt.% of the total amt. of the vitamin E and lipids.
The proposed study will evaluate the safety and efficacy of brodalumab in improving and resolving irAEs in patients treated with brodalumab. Eligible subjects must have an immune-related adverse event with the intent to treat it with steroids. Subjects will receive subcutaneous brodalumab for 24 weeks. Peripheral blood will be collected at all in-person study visits for mechanistic studies. Participants will be evaluated at week 0, 1, 2, 4, and then every 4 weeks after that until week 24 as dictated by the standard of care using a combination of telemedicine and face-to-face evaluations. Additional safety follow-up visits will occur at weeks 28 and 36. All patients will have the Columbia Suicide Severity Rating Scale (C-SSRS), and Patient Health Questionnaire-9 (PHQ-9) administered at all visits. The treatment protocol consists of subcutaneous brodalumab 210 mg administered at baseline and then at weeks 0, 1, and 2, then bi-weekly for a total of 24 weeks (the current FDA-approved dosing for plaque psoriasis). Glucocorticoids may be used at baseline at the discretion of the investigators, with the goal of tapering off of steroids over 4-8 weeks if tolerated (see proposed taper in appendix). Continued treatment beyond the 24-week course can be evaluated by the treating investigator and the Sponsor-Investigator, weighing risks versus clinical benefit.
Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
Provided are systems and methods for pre-qualification of candidate patient populations. The systems and methods can be are configured for inexpensive, selective, and lightweight procedures that identify patients against desired criteria. In some implementations, willing participants are enrolled in pre-treatment execution of a clinical trial. The participants are issued telemedicine monitoring devices for capturing and reporting health information. For example, non-invasive monitoring devices can be issued to track mobility, exertion, blood pressure, heart rate, brain activity, among other options. The participants can be monitored for time periods similar to actual trial execution phases (e.g., monitoring periods of years can be used) or monitored for any length of time to develop comparable clinical histories for the participants.
PURPOSE:To identify effectively a BCG vaccine-sensitized living body and a human type tubercle bacillus-sensitized living body by using the D material derived from BCG bacilli as a tuberculin antigen. CONSTITUTION:A D material which is the novel and powerful tuberculin antigen derived from tubercle bacilli is isolated in early time and is verified later that the D material obtd. from the BCG bacilli in particular is the tuberculin antigen extremely powerful as compared with refined tuberculin (PPD) in a BCG vaccine-sensitized living body. On the other hand, it is found that said material exhibits extremly weak activity only as compared to PPD in a human type tubercle bacillus-sensitized living body, unlike the BCG vaccine-sensitized living body. Such characteristic is utilized for the diagnozing agent of this invention in which the D material derived from the BCG bacilli is used as an effective component to induce the specific reaction with the BCG vaccine-sensitized living body. The effective identification of the BCG vaccine-sensitized living body and the human type tubercle bacillus-sensitized living body is thus made possible.
Currently, available findings coming mainly from allo-HSCT (hhematopoietic cell transplantation) studies, link particular changes in microbiota with overall survival and post-transplant disorders, especially GvHD. According to limited data, further evaluation of associations between the alterations in microbiome composition and toxicities. Detail investigation of both the microbiome and host immune system may help to find microbiome markers useful for very early identification of patients at risk for major transplant-related complications. This might bring the possibility to modulate the gut microbiota in patient´s specific manner to achieve optimal therapeutic outcome and follow-up, while avoiding severe post-transplant complications.

This is prospective, single center, non-randomized, hypothesis generating study. Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including micro RNA (miR) and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S (RNA component of the small subunit of a prokaryotic ribosome) rRNA (ribosomal ribonucleic acid) gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used including characterization of potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.